BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21972713)

  • 1. [Prognostic value of the molecular markers cyclin D1 and P53 in patients with lung cancer].
    Uchikov A; Hadjiev B; Dimitrov I; Prisadov G; Uchikova E; Batashki A; Ganchevska P
    Khirurgiia (Sofiia); 2010; (6):19-22. PubMed ID: 21972713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
    Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
    Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
    Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
    Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
    Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
    Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2.
    Nguyen VN; Mirejovský P; Mirejovský T; Melínová L; Mandys V
    Acta Histochem; 2000 Aug; 102(3):323-38. PubMed ID: 10990069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis.
    Caputi M; De Luca L; Papaccio G; D'Aponte A; Cavallotti I; Scala P; Scarano F; Manna M; Gualdiero L; De Luca B
    Eur J Histochem; 1997; 41(2):133-8. PubMed ID: 9271706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.
    Dosaka-Akita H; Hommura F; Mishina T; Ogura S; Shimizu M; Katoh H; Kawakami Y
    Cancer Res; 2001 Mar; 61(6):2500-4. PubMed ID: 11289121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in non-small cell lung carcinoma and their association with the prognosis].
    Liang RY; Liao ZS; Jiang SP; Zhang W; Li JG; Zheng DH
    Ai Zheng; 2003 Jan; 22(1):86-90. PubMed ID: 12561444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer.
    Ko E; Kim Y; Park SE; Cho EY; Han J; Shim YM; Park J; Kim DH
    Lung Cancer; 2012 Aug; 77(2):401-6. PubMed ID: 22534667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis.
    Pasz-Walczak G; Kordek R; Faflik M
    Pathol Res Pract; 2001; 197(10):683-9. PubMed ID: 11700890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.
    Keum JS; Kong G; Yang SC; Shin DH; Park SS; Lee JH; Lee JD
    Br J Cancer; 1999 Sep; 81(1):127-32. PubMed ID: 10487623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung.
    Ikehara M; Oshita F; Ito H; Ohgane N; Suzuki R; Saito H; Yamada K; Noda K; Mitsuda A; Kameda Y
    Oncol Rep; 2003; 10(1):137-9. PubMed ID: 12469159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of p53, p21 (Waf1/Cip1), and cyclin D1 protein expression in esophageal cancer patients.
    Hirai T; Kuwahara M; Yoshida K; Osaki A; Toge T
    Anticancer Res; 1999; 19(5C):4587-91. PubMed ID: 10650815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer.
    Khoury T; Alrawi S; Ramnath N; Li Q; Grimm M; Black J; Tan D
    Clin Lung Cancer; 2009 Jan; 10(1):58-66. PubMed ID: 19289374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy.
    Hayakawa K; Mitsuhashi N; Hasegawa M; Saito Y; Sakurai H; Ohno T; Maebayashi K; Ebara T; Hayakawa KY; Niibe H
    Anticancer Res; 1998; 18(5B):3685-8. PubMed ID: 9854477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
    Bilyk OO; Pande NT; Buchynska LG
    Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.